Japanese BAY86-9766 Monotherapy Phase I Study

Inclusion Criteria:

* Japanese patients, who are at least 18 years of age at the first screening examination/ visit, with advanced or refractory solid tumors not amenable to standard therapy.
* Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, with no current involvement in the central nervous system (CNS)
* At least one measurable lesion or evaluable disease according to response evaluation criteria in solid tumors (RECIST) version 1.1
* Eastern cooperative oncology group performance status (ECOG-PS) of 0 or 1
* Life expectancy of at least 12 weeks

Exclusion Criteria:

* Use of any anti-cancer therapy including chemotherapy, investigational agents or devices and immunotherapy within 4 weeks of the first dose of study medication
* Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management
* Known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C
* Inadequate bone marrow, liver and renal function
* Inability to swallow oral medications or any condition that could affect the absorption of orally administered drugs
* Concomitant treatment with cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers, and CYP2C19 inhibitors/ inducers